Not logged inTreatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary End Points From the EMBARK Trial
Shore, Neal D.; Gleave, Martin; De Giorgi, Ugo; Rannikko, Antti; Pieczonka, Christopher M.; Sridharan, Swetha; Brasso, Klaus; Woo, Henry H.; Gomez Caamano, Antonio; Saranchuk, Jeff W.; Nordquist, Luke T.; Ferreira, Ubirajara; Tang, Yiyun; Rosbrook, Brad; Haas, Gabriel P.; Rosales, Matt; Zohren, Fabian; Tarazi, Jamal; Freedland, Stephen J. .png)
Share.png)
SavePlain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancerAgarwal, Neeraj; Azad, Arun A.; Carles, Joan; Fay, Andre P.; Matsubara, Nobuaki; Heinrich, Daniel; Szczylik, Cezary; Giorgi, Ugo De; Joung, Jae Young; Fong, Peter C.; Voog, Eric; Jones, Robert J.; Shore, Neal D.; Dunshee, Curtis; Zschabitz, Stefanie; Oldenburg, Jan; Lin, Xun; Healy, Cynthia G.; Di Santo, Nicola; Zohren, Fabian; Fizazi, Karim Share Save 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
